CLDX logo

CLDX
Celldex Therapeutics Inc.

9,725
Mkt Cap
$2.46B
Volume
157,360.00
52W High
$35.79
52W Low
$18.55
PE Ratio
-7.34
CLDX Fundamentals
Price
$30.77
Prev Close
$31.34
Open
$31.50
50D MA
$32.07
Beta
1.16
Avg. Volume
1.15M
EPS (Annual)
-$3.90
P/B
4.57
Rev/Employee
$7,803.03
$1,292.18
Loading...
Loading...
News
all
press releases
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
More News
News Placeholder
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) delivered earnings and revenue surprises of +3.53% and -1.83%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·14d ago
News Placeholder
Pictet Asset Management Holding SA Reduces Holdings in Celldex Therapeutics, Inc. $CLDX
Pictet Asset Management Holding SA reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.1% during the fourth quarter, according to the company in its most...
MarketBeat·17d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Shares Pass Above 200 Day Moving Average - What's Next?
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200-Day Moving Average - Here's Why...
MarketBeat·20d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...
MarketBeat·28d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays
Barclays raised shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and set a $45.00 price target for the company in a report on Monday...
MarketBeat·28d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Here's What Happened
Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High - Time to Buy...
MarketBeat·1mo ago
News Placeholder
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com...
MarketBeat·1mo ago
News Placeholder
Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX
Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,618 shares of the biopharmaceutical company's stock...
MarketBeat·1mo ago
<
1
2
...
>

Latest CLDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.